ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION

Purpose of the study: to study the efficacy and safety of Ranibizumab in patients with pathologic myopia and choroidal neovascularization (CNV). 22 patients (22 eyes) with myopic CNV were included in the study. Mean age was 54.0 ± 14.4 years, axial length -28.25± 1.9 mm,follow-up-from 12 to 59 month...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. A. Korotkikh, E. V. Bobykin, G. V. Zhiborkin, A. Y. Anashkin, A. V. Berezin
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2016
Materias:	pathologic myopia ranibizumab myopic choroidal neovascularization compliance Science Q
Acceso en línea:	https://doaj.org/article/113add6fa8974e6a8fda12e9e7207145
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:113add6fa8974e6a8fda12e9e7207145
record_format	dspace
spelling	oai:doaj.org-article:113add6fa8974e6a8fda12e9e72071452021-11-23T06:14:36ZANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION2541-94202587-959610.12737/23745https://doaj.org/article/113add6fa8974e6a8fda12e9e72071452016-11-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/322https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596Purpose of the study: to study the efficacy and safety of Ranibizumab in patients with pathologic myopia and choroidal neovascularization (CNV). 22 patients (22 eyes) with myopic CNV were included in the study. Mean age was 54.0 ± 14.4 years, axial length -28.25± 1.9 mm,follow-up-from 12 to 59 months (mean follow-up - 26.9 ± 13.8 months). Ranibizumab was administered intravitreally according to the label in patients with active CNV confirmed by fluorescein angiography. The treatment was shown to have favorable early and long-term outcomes. For example, visual acuity increased (from 0.25 to 0.54; p < 0.01), central retinal thickness decreased (from 335.8 to 273.25 μm; p < 0,05), subretinal neovascular membrane area decreased (from 1272 to 969 ßm; p < 0.05). Clinically significant treatment complications were not observed. Conclusions: The study confirmed high efficacy and safety of anti-angiogenic therapy.S. A. KorotkikhE. V. BobykinG. V. ZhiborkinA. Y. AnashkinA. V. BerezinScientific Сentre for Family Health and Human Reproduction Problemsarticlepathologic myopiaranibizumabmyopic choroidal neovascularizationcomplianceScienceQRUActa Biomedica Scientifica, Vol 1, Iss 6, Pp 66-70 (2016)
institution	DOAJ
collection	DOAJ
language	RU
topic	pathologic myopia ranibizumab myopic choroidal neovascularization compliance Science Q
spellingShingle	pathologic myopia ranibizumab myopic choroidal neovascularization compliance Science Q S. A. Korotkikh E. V. Bobykin G. V. Zhiborkin A. Y. Anashkin A. V. Berezin ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
description	Purpose of the study: to study the efficacy and safety of Ranibizumab in patients with pathologic myopia and choroidal neovascularization (CNV). 22 patients (22 eyes) with myopic CNV were included in the study. Mean age was 54.0 ± 14.4 years, axial length -28.25± 1.9 mm,follow-up-from 12 to 59 months (mean follow-up - 26.9 ± 13.8 months). Ranibizumab was administered intravitreally according to the label in patients with active CNV confirmed by fluorescein angiography. The treatment was shown to have favorable early and long-term outcomes. For example, visual acuity increased (from 0.25 to 0.54; p < 0.01), central retinal thickness decreased (from 335.8 to 273.25 μm; p < 0,05), subretinal neovascular membrane area decreased (from 1272 to 969 ßm; p < 0.05). Clinically significant treatment complications were not observed. Conclusions: The study confirmed high efficacy and safety of anti-angiogenic therapy.
format	article
author	S. A. Korotkikh E. V. Bobykin G. V. Zhiborkin A. Y. Anashkin A. V. Berezin
author_facet	S. A. Korotkikh E. V. Bobykin G. V. Zhiborkin A. Y. Anashkin A. V. Berezin
author_sort	S. A. Korotkikh
title	ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
title_short	ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
title_full	ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
title_fullStr	ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
title_full_unstemmed	ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION
title_sort	anti-angiogenic therapy in patients with pathologic myopia and choroidal neovascularization
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2016
url	https://doaj.org/article/113add6fa8974e6a8fda12e9e7207145
work_keys_str_mv	AT sakorotkikh antiangiogenictherapyinpatientswithpathologicmyopiaandchoroidalneovascularization AT evbobykin antiangiogenictherapyinpatientswithpathologicmyopiaandchoroidalneovascularization AT gvzhiborkin antiangiogenictherapyinpatientswithpathologicmyopiaandchoroidalneovascularization AT ayanashkin antiangiogenictherapyinpatientswithpathologicmyopiaandchoroidalneovascularization AT avberezin antiangiogenictherapyinpatientswithpathologicmyopiaandchoroidalneovascularization
_version_	1718416992070795264

ANTI-ANGIOGENIC THERAPY IN PATIENTS WITH PATHOLOGIC MYOPIA AND CHOROIDAL NEOVASCULARIZATION

Ejemplares similares